173 related articles for article (PubMed ID: 15386408)
1. Mutations of BRAF and RAS are rare events in germ cell tumours.
Sommerer F; Hengge UR; Markwarth A; Vomschloss S; Stolzenburg JU; Wittekind C; Tannapfel A
Int J Cancer; 2005 Jan; 113(2):329-35. PubMed ID: 15386408
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
[TBL] [Abstract][Full Text] [Related]
3. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours.
Ahmad F; Surve P; Natarajan S; Patil A; Pol S; Patole K; Das BR
Cancer Genet; 2020 Feb; 241():42-50. PubMed ID: 31653608
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma.
Aust DE; Haase M; Dobryden L; Markwarth A; Löhrs U; Wittekind C; Baretton GB; Tannapfel A
Int J Cancer; 2005 Jul; 115(5):673-7. PubMed ID: 15704157
[TBL] [Abstract][Full Text] [Related]
5. Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors.
Cárcano FM; Lengert AH; Vidal DO; Scapulatempo Neto C; Queiroz L; Marques H; Baltazar F; Berardinelli GN; Martinelli CM; da Silva EC; Reis RM; Lopes LF
Andrology; 2016 Sep; 4(5):866-72. PubMed ID: 27153176
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.
McIntyre A; Summersgill B; Spendlove HE; Huddart R; Houlston R; Shipley J
Neoplasia; 2005 Dec; 7(12):1047-52. PubMed ID: 16354586
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors.
Boublikova L; Bakardjieva-Mihaylova V; Skvarova Kramarzova K; Kuzilkova D; Dobiasova A; Fiser K; Stuchly J; Kotrova M; Buchler T; Dusek P; Grega M; Rosova B; Vernerova Z; Klezl P; Pesl M; Zachoval R; Krolupper M; Kubecova M; Stahalova V; Abrahamova J; Babjuk M; Kodet R; Trka J
Cancer Lett; 2016 Jul; 376(2):367-76. PubMed ID: 27085458
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and molecular features of late relapses in non-seminomas.
Mayer F; Wermann H; Albers P; Stoop H; Gillis AJ; Hartmann JT; Bokemeyer CC; Oosterhuis JW; Looijenga LH; Honecker F
BJU Int; 2011 Mar; 107(6):936-43. PubMed ID: 20955261
[TBL] [Abstract][Full Text] [Related]
10. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
11. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors.
Tannapfel A; Vomschloss S; Karhoff D; Markwarth A; Hengge UR; Wittekind C; Arnold R; Hörsch D
Am J Clin Pathol; 2005 Feb; 123(2):256-60. PubMed ID: 15842051
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors.
Biermann K; Heukamp LC; Steger K; Zhou H; Franke FE; Sonnack V; Brehm R; Berg J; Bastian PJ; Muller SC; Wang-Eckert L; Buettner R
Cancer Genomics Proteomics; 2007; 4(5):359-67. PubMed ID: 17993720
[TBL] [Abstract][Full Text] [Related]
13. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
[TBL] [Abstract][Full Text] [Related]
14. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.
Mata DA; Yang SR; Ferguson DC; Liu Y; Sharma R; Benhamida JK; Al-Ahmadie HA; Chakravarty D; Solit DB; Tickoo SK; Gupta S; Arcila ME; Ladanyi M; Feldman DR; Reuter VE; Vanderbilt CM
Urology; 2020 Oct; 144():111-116. PubMed ID: 32721511
[TBL] [Abstract][Full Text] [Related]
15. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Characterization of Bilateral Testicular Germ Cell Tumors With Immunohistochemical Evaluation of Mismatch Repair and
Al-Obaidy KI; Trevino KE; Idrees MT
Int J Surg Pathol; 2019 Sep; 27(6):619-623. PubMed ID: 30983459
[TBL] [Abstract][Full Text] [Related]
17. Differences in global DNA methylation of testicular seminoma are not associated with changes in histone modifications, clinical prognosis, BRAF mutations or gene expression.
Pedersen LH; Nielsen JE; Daugaard G; Hansen TV; Rajpert-De Meyts E; Almstrup K
Cancer Genet; 2016 Nov; 209(11):506-514. PubMed ID: 27886677
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
Knobbe CB; Reifenberger J; Reifenberger G
Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
[TBL] [Abstract][Full Text] [Related]
19. Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization.
Moul JW; Theune SM; Chang EH
Genes Chromosomes Cancer; 1992 Sep; 5(2):109-18. PubMed ID: 1381946
[TBL] [Abstract][Full Text] [Related]
20. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
